GILD Gilead Sciences
FY2025 10-K
Gilead Sciences (GILD) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Biopharmaceutical company focused on HIV, viral hepatitis, COVID-19, and oncology; commercial portfolio of 25+ therapies distributed across 35+ countries via wholesale channel (~90% of U.S. sales through 3 wholesalers)
- • Yeztugo/Yeytuo (lenacapavir) approved as first and only twice-yearly HIV PrEP option in both U.S. and EU; multiple BLA filings pending for anitocabtagene autoleucel (multiple myeloma) and expanded Trodelvy indications in TNBC first-line and NSCLC
Management Discussion & Analysis
- • Revenue $29.4B in 2025, up 2% YoY; HIV +6% to $20.8B best performer; Veklury -49% to $911M worst performer
- • Product gross margin 78.4% vs 78.2% (+29 bps); SG&A down 5% to $5.8B; effective tax rate 13.1% vs 30.5%
Risk Factors
- • IRA + MFN pricing: Biktarvy selected for Medicare price negotiation effective 2028; Gilead signed Dec 2025 agreement implementing MFN Medicaid prices and pausing Section 232 tariffs for 3 years
- • Pharmaceutical tariff exposure: U.S. administration announced plans for up to 100% tariffs on imported branded/patented pharmaceuticals; Gilead sources significant raw materials and intermediates from outside U.S.
Financial SummaryXBRL
Revenue
$29.4B
Net Income
$8.5B
Operating Margin
34.0%
Net Margin
28.9%
ROE
37.5%
Total Assets
$59.0B
EPS (Diluted)
$6.78
Operating Cash Flow
$10.0B
Source: XBRL data from Gilead Sciences FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Annual Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.